The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies (2203.02182v1)

Abstract: The ICH E9 (R1) Estimands Guidance1 terminology does not completely address the conceptual needs of time-to-event estimands in the complex oncology context. We previously described how censoring and censoring mechanisms for time-to-event endpoints can be embedded into the ICH E9 (R1) Estimands Guidance terminology. This second paper by the Pharmaceutical Industry Working Group on Estimands in Oncology Censoring Mechanisms Subteam discusses special issues in the oncology clinical context that may require different approaches than some other therapeutic areas as well as an extensions of the ICH E9 (R1) guidance. The concept of censoring is discussed in the broader context of occluding events, with occlusion representing any loss to further follow-up and/or removal of further collected data from analysis. Occlusion constitutes a broader concept than the estimand guidance's intercurrent event and terminal event terminology and is appropriate to describe and handle situations like withdrawal from assessments or situations where the requirements of different estimands conflict. We characterize, provide additional details, practical implications, and examples on the application of each estimands strategy for handling occluding events.